

Review of: "Sotorasib Treatment Could Worsen the Prognosis of Advanced KRASG12C-Mutated Non-Small Cell Lung Cancer"

Faraat Ali¹

¹ Charles University, Prague, Czech Republic

Potential competing interests: No potential competing interests to declare.

Add some recent FDA-approved NSCLC references: Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers, May 2022, Archives of Pharmacal Research, 45(7)

DOI: 10.1007/s12272-022-01385-3

Add the chemical structure of Sotorasib and other FDA-approved drugs.

Compare Sotorasib with Pralsetinib in NSCLC in terms of efficacy and other DMPK parameters.